Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CCND1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CCND1 overexpression	Mantle Cell Lymphoma	CCND1 overexpression	Mantle Cell Lymphoma	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2
CCND1 overexpression	Breast Cancer	CCND1 overexpression	Breast Cancer	AMG 386 Resistant: C3 – Early Trials AMG 386 Resistant : C3	AMG 386 Resistant: C3 – Early Trials AMG 386 Resistant : C3
CCND1 overexpression	Breast Cancer	CCND1 overexpression	Breast Cancer	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3
CCND1 overexpression	Multiple Myeloma	CCND1 overexpression	Multiple Myeloma	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3
CCND1 overexpression	Estrogen Receptor Positive Breast Cancer	CCND1 overexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3
CCND1 overexpression	Squamous Cell Skin Cancer	CCND1 overexpression	Squamous Cell Skin Cancer	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
CCND1 overexpression	Ependymoma	CCND1 overexpression	Ependymoma	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D
CCND1 overexpression	Breast Cancer	CCND1 overexpression	Breast Cancer	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D